A Pilot Study of Addition of Amifostine to Melphalan, Carboplatin, Etoposide, and Cyclophosphamide With Autologous Hematopoietic Stem Cell Transplantation in Pediatric Solid Tumors–A Pediatric Blood and Marrow Transplant Consortium Study

M. Fevzi Ozkaynak,Indira Sahdev,Thomas G. Gross,John E. Levine,Alexandra Cheerva,Michael Richards,Marta K. Rozans,Peter J. Shaw,Richard Kadota

A Pilot Study of Addition of Amifostine to Melphalan, Carboplatin, Etoposide, and Cyclophosphamide With Autologous Hematopoietic Stem Cell Transplantation in Pediatric Solid Tumors–A Pediatric Blood and Marrow Transplant Consortium Study

2008

M. Fevzi Ozkaynak
Indira Sahdev
Thomas G. Gross
John E. Levine
Alexandra Cheerva
Michael Richards
Marta K. Rozans
Peter J. Shaw
Richard Kadota

Limited information is available regarding the use of amifostine in pediatric hematopoietic stem cell transplant (HSCT) patients. Melphalan, carboplatin, etoposide ± cyclophosphamide is a commonly used preparatory regimen in pediatric solid tumor HSCT. Therefore, we decided to determine the feasibil

Keywords:

Carboplatin
Hematopoietic stem cell transplantation
Etoposide
Amifostine
Pathology
Oncology
Regimen
Melphalan
Hematopoietic stem cell
Internal medicine
Medicine
Cyclophosphamide

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations